RxDoctor Payments Data

Jack Adcock, DO

Gynecology · Joplin, MONPI 1669487054

Payments from drug & device makers

What this record shows

This record is dominated by education: $11,674 of the $18,336 with a category attached, or 63.7%. Intuitive Surgical accounts for 75.8% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2022 at $13,615 and has fallen 86.5% since, to $1,836 in 2024.

$18,336in general payments, 2019–2025

Across 162 payments — averaging $113.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$14K
  • Axonics, Inc.$2K
  • AbbVie$673
  • Astellas Pharma US Inc$439
  • Urovant Sciences Inc$193
  • Amgen$182
  • plus $918 from 22 others

What the payments were for

  • Travel & lodging$3,43219%
  • Food & beverage$2,64514%
  • Education$11,67464%
  • Gifts$5853%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,336 in reported general payments places this provider in the 80th percentile of 38 gynecology providers in Missouri.

See all gynecology providers in Missouri

Medicare billing

Part B allowed, 2024
$39,022
Medicare patients
154
Services billed
317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron211$90,925
GemtesaVibegron85$54,589
Tolterodine Tartrate ErTolterodine Tartrate97$4,818
Estradiol146$3,159
Trospium Chloride72$2,476
Clobetasol Propionate22$1,874
Methenamine Hippurate58$1,278
Clindamycin Phosphate21$1,260
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst75$1,237
Fesoterodine Fumarate ErFesoterodine Fumarate19$683
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet21$584
Solifenacin Succinate12$277
Nystatin15$254
Oxybutynin Chloride26$180
Oxybutynin Chloride ErOxybutynin Chloride38$152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$439$90,925211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 38 gynecology providers in Missouri.

Other gynecology in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →